Blood lactate levels in patients receiving first- or second generation antipsychotics

Croatian Medical Journal

Volumn 52, Issue 1, 2011, Pages 41-47

  Glavina, Trpimir ^a   Mrass, Damir ^a   Dodig, Tajana ^b   Glavina, Gordana ^a   Pranić, Shelly ^c   Uglešić, Boran ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b Referentni centar za Alzheimerovu bolest i psihijatriju sta rijeivo t ne dobi   (Croatia)

^c UNIVERSITY OF SPLIT   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; LACTIC ACID; OLANZAPINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PSYCHOSIS; RATING SCALE; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOPAMINE ANTAGONISTS; DRUG MONITORING; HALOPERIDOL; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PARKINSON DISEASE, SECONDARY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 79951846311     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2011.52.41     Document Type: Article

References (41)

1. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry. 2000;61 Suppl 8:5-11. Medline:10811237
2. Marder SR. Newer antipsychotics. Curr Opin Psychiatry. 2000;13:11-4. doi:10.1097/00001504-200001000-00003
3. Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a crosssectional study. Diabetologia. 2005;48:215-21. doi:10.1007/s00125-004-1641-y Medline:15688206
4. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19-28. doi:10.1001/archpsyc.62.1.19
5. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54:862-71. doi:10.2337/diabetes.54.3.862
6. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm. 2000;57:238-55.
7. Stahl SM. Essential psychopharmacology. New York (NY): Cambridge University Press; 1996.
8. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49:1163-72.
9. Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry. 2000;34:355-69.
10. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q. 1992;63:51-70. doi:10.1007/BF01064682
11. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581-9. doi:10.1016/S0140-6736(03)13306-5
12. Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci. 2001;251:141-6. doi:10.1007/s004060170049
13. Nichol AD, Egi M, Pettila V, Bellomo R, French C, Hart G, et al. Relative hyperlactatemia and hospital mortality in critically ill patients: a retrospective multi-centre study. Crit Care. 2010;14:R25. doi:10.1186/cc8888
14. Bakker J, de Lima AP. Increased blood lacate levels: an important warning signal in surgical practice. Crit Care. 2004;8:96-8. doi:10.1186/cc2841
15. Adrogue HJ, Madias NE. Management of life-threatening acidbase disorders. First of two parts. N Engl J Med. 1998;338:26-34.
16. De Backer D. Lactic acidosis. Intensive Care Med. 2003;29:699-702.
17. Adrogue HJ, Madias NE. Management of life-threatening acid-base disorders. Second of two parts. N Engl J Med. 1998;338:107-11.
18. Smith I, Kumar P, Molloy S, Rhodes A, Newman PJ, Grounds RM, et al. Base excess and lactate as prognostic indicators for patients admitted to intensive care. Intensive Care Med. 2001;27:74-83. doi:10.1007/s001340051352
19. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62:15-26.
20. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry. 1968;124:978-82.
21. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther. 1970;11:883-9.
22. Amdisen A. Drug-produced obesity. Experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull. 1964;11:182-9.
23. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidoneassociated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23:735-44. doi:10.1592/phco.23.6.735.32178
24. Bustillo JR, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry. 1996;153:817-9.
25. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 suppl 1:1-93. doi:10.2165/00023210-200519001-00001
26. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59:294-9. doi:10.4088/JCP.v59n0604
27. McCracken M, Ainsworth B, Hackney AC. Effects of the menstrual cycle phase on the blood lactate responses to exercise. Eur J Appl Physiol Occup Physiol. 1994;69:174-5. doi:10.1007/BF00609412
28. Stephenson LA, Kolka MA, Wilkerson JE. Metabolic and thermoregulatory responses to exercise during the human menstrual cycle. Med Sci Sports Exerc. 1982;14:270-5. doi:10.1249/00005768-198204000-00003
29. Sutton JR, Jurkowski JE, Keane P, Walker WHC, Jones NL, Toews CJ. Plasma-catecholamine, insulin, glucose and lactate responses to exercise in relation to the menstrual-cycle. Med Sci Sports. 1980;12:83-4.
30. Jurkowski JE, Jones NL, Toews CJ, Sutton JR. Effects of menstrual cycle on blood lactate, O2 delivery, and performance during exercise. J Appl Physiol. 1981;51:1493-9.
31. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al. Metformin addition attenuates olanzapine induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebocontrolled study. Am J Psychiatry. 2008;165:352-8. doi:10.1176/appi.ajp.2007.07010079
32. Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol. 1995;10:239-44. doi:10.1097/00004850-199511000-00005
33. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76:247-65. doi:10.1016/j.schres.2005.02.013
34. Uribarri J, Oh MS, Carroll HJ. D-lactic acidosis. A review of clinical presentation, biochemical features, and pathophysiologic mechanisms. Medicine. 1998;77:73-82. doi:10.1097/00005792-199803000-00001
35. Tello R, Crewson PE. Hypothesis testing II: means. Radiology. 2003;227:1-4. doi:10.1148/radiol.2271020085
36. Rollema H, Skolnik M, D'Engelbronner J, Igarashi K, Usuki E, Castagnoli N Jr. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther. 1994;268:380-7.
37. Kliegel A, Losert H, Sterz F, Holzer M, Zeiner A, Havel C, et al. Serial lactate determinations for prediction of outcome after cardiac arrest. Medicine. 2004;83:274-9. doi:10.1097/01.md.0000141098.46118.4c
38. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396-404. doi:10.1176/appi.ajp.160.8.1396
39. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:1218-26. doi:10.1001/archpsyc.60.12.1218
40. Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month randomized, randomized double-blind, placebocontrolled discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int J Geriatr Psychiatry. 2010 Dec 28. [Epub ahead of print] doi:10.1002/gps.2630
41. Bobo WV, Jayathilake K, Lee MA, Meltzer HY. Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. Hum Psychopharmacol. 2009;24:415-22. doi:10.1002/hup.1036